Biotech | September 22, 2022
Charsire's new drug aims to capture dementia treatment market
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
First and only biologic approved in the EU in patients with severe asthma with no phenotype or biomarker limitations
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
iNCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy
CHMP recommendation based on safety, tolerability, and immunogenicity data from a Phase 2/3 trial of the Omicron BA.1-adapted bivalent vaccine
The purpose of the conclave was to discuss the present situation of body-organ-eye donation in India and find solutions to the challenges ahead in future
Spesolimab is a monoclonal antibody that inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for the treatment of generalized pustular psoriasis flares
Subscribe To Our Newsletter & Stay Updated
